All In Biotech

Drug Trial Radar · NCT07861542

Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

A Phase 4 Open-label, Single-arm Study to Evaluate the Safety and Immunogenicity of an Omicron Subvariant-based SARS-CoV-2 Recombinant Spike (rS) Vaccine Adjuvanted With Matrix-M in Participants ≥ 65 Years of Age and Participants 12 Through 64 Years of Age Who Are at Increased Risk for Severe COVID-19 Illness

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

669

Actual

Start

Oct 1, 2026

Primary completion

Nov 26, 2026

Study completion Jan 27, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of a single dose of Sanofi's Omicron subvariant-based Nuvaxovid in participants ≥ 65 years of age and participants 12 through 64 years of age who have at least one underlying condition that puts them at increased risk for severe outcomes of COVID-19 and who have been previously vaccinated with a COVID-19 vaccine ≥ 90 days prior to study vaccination. Study details include: * The study duration will be approximately 3 months per participant. * Study intervention will be administered via a single intramuscular (IM) injection into the deltoid muscle on Day 1. * The visit frequency will be Day 1, Day 9 telephone call, Day 29, and Day 91 telephone call (3-month safety follow-up).

Conditions

  • COVID-19

Interventions

  • Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-MBiological

    Pharmaceutical form: Sterile suspension for injection Route of administration: Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Fold Rise (GMFR) in pseudovirus neutralizing antibody titers (ID50) against the Omicron subvariant included in the vaccine formulation from pre-vaccination to 28 days post-vaccination.Time frame: Day 1 (pre-vaccination) and Day 29 (28 days after vaccination)

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Site #: 8400005

    Fair Oaks, California

  • Site #: 8400002

    Doral, Florida

  • Site #: 8400008

    Atlanta, Georgia

  • Site #: 8400015

    Decatur, Georgia

  • Site #: 8400011

    Melrose Park, Illinois

  • Site #: 8400019

    Sioux City, Iowa

  • Site #: 8400009

    Lenexa, Kansas

  • Site #: 8400001

    Lafayette, Louisiana

  • Site #: 8400003

    New Orleans, Louisiana

  • Site #: 8400024

    Rockville, Maryland

  • Site #: 8400012

    Southfield, Michigan

  • Site #: 8400023

    Grand Island, Nebraska

  • Site #: 8400004

    Omaha, Nebraska

  • Site #: 8400021

    Omaha, Nebraska

  • Site #: 8400016

    Cincinnati, Ohio

  • Site #: 8400007

    Philadelphia, Pennsylvania

  • Site #: 8400018

    Austin, Texas

  • Site #: 8400017

    Frisco, Texas

  • Site #: 8400014

    Houston, Texas

  • Site #: 8400013

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.